文献类型：期刊文献

中文题名：扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化30例临床观察

英文题名：Clinical Observation on Right-Supporting Liver-Emolliating Formula Combined With Lamivudine for 30 Cases of Liver Fibrosis in Chronic Hepatitis B

作者：刘俊宏[1];汪龙德[1];王敏[2];毛兰芳[3]

第一作者：刘俊宏

机构：[1]甘肃中医学院附属医院;[2]贵阳中医学院第一附属医院;[3]甘肃中医学院

第一机构：甘肃中医药大学第二附属医院

年份：2014

卷号：55

期号：15

起止页码：1307

中文期刊名：中医杂志

外文期刊名：Journal of Traditional Chinese Medicine

收录：CSTPCD;;北大核心:【北大核心2011】；CSCD:【CSCD2013_2014】；

语种：中文

中文关键词：慢性乙型肝炎;肝纤维化;扶正柔肝方

外文关键词：chronic hepatitis B; liver fibrosis; Right-Supporting Liver-Emolliating Formula

摘要：目的观察扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化的临床疗效。方法将60例患者随机分为治疗组和对照组各30例。两组患者均口服拉米夫定片,每次100mg,每日1次。治疗组加用扶正柔肝方,每日1剂,早晚温服。对照组加用大黄虫胶囊治疗,每次1.6g口服,每日两次。两组均以8周为1个疗程,共治疗6个疗程。治疗前后分别观察两组中医证候积分、肝功能指标[包括丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、总胆红素(TBiL)、血清白蛋白(ALB)]、血清肝纤维化指标[包括透明质酸(HA)、IV型胶原(Ⅳ-C)、Ⅲ型前胶原(PCⅢ)和层黏蛋白(LN)]、AST与血小板计数比值指数(APRI)与ALT/AST/血小板指数(TPRI),彩色多普勒超声仪检测门静脉内径、脾静脉内径及脾脏厚度。结果治疗组临床疗效总有效率为93.33%,对照组为70.00%,治疗组明显高于对照组(P<0.05)。两组患者治疗后与治疗前比较,中医证候积分、门静脉内径、脾静脉内径、脾脏厚度、肝功能及肝纤维化标志物检测结果均明显降低(P<0.05或P<0.01),并且治疗组均低于对照组(P<0.05或P<0.01)。结论扶正柔肝方联合拉米夫定片治疗慢性乙型肝炎肝纤维化疗效确切,可明显改善临床症状,减轻肝脏损伤。
Objective To observe the efficacy of Right-Supporting Liver-Emolliating Formula for liver fibrosis in chronic hepatitis B. Methods Sixty patients were randomized into the treatment group and control group, with 30 in each. The patients in both groups were orally taken Lamivudine Tablets （ 100mg/each time, once daily）. The treatment group was added with Right-Supporting Liver-Emolliating Formula one dose daily. The control group was added with Dahuang Zhechong Capsules （ 1.6 g/each time, twice daily）. One treatment course lasted for 8 weeks and the treatment lasted for 6 courses. The TCM syndrome scores, alanine aminotransferase （ALT）, aspartate aminotrans- ferase （ AST）, total bilirubin （ TBil）, albumin （ ALB）, hyaluronic acid （ HA）, IV-collagen （ 1V-C ）, procollagen- 11I （PC-Ill）, laminin （LN）, AST to platelet ratio index （APRI） and ALT/AST/platelet ratio index （TPRI） were observed before and after treatment. The portal vein diameter, splenic vein diameter and thickness of spleen were de- tected by color Doppler ultrasound. Results The total effective rate of the treatment group and control group was 93.33% and 70.00% respectively, with a significant difference between groups （P 〈 0. 05 ）. The TCM syndrome scores, indicators of color Doppler ultrasound （ except the control group）, liver function （ except ALB in the control group） and markers of liver fibrosis in both groups were significantly decreased after treatment （P 〈 0.05 or P 〈 0.01 ）, especially in the treatment group （P 〈 0.05 or P 〈 0. 01 ）. Conclusion Right-Supporting Liver- Emolliating Formula is effective for liver fibrosis in chronic hepatitis B and can improve symptoms and reduce liver injury.